Table 2.
% (n) of subjects with treatment switch (n=59)* | % (n) of treatment switches (n=74) | |
---|---|---|
d4T to AZT | 42 (25) | 34 (25) |
AZT to d4T | 14 (8) | 11 (8) |
NVP to EFV | 7 (4) | 5 (4) |
EFV to NVP | 10 (6) | 8 (6) |
1st to 2nd line therapy | 12 (7) | 10 (7) |
Other switches | 31 (18) | 32 (24) |
d4T: Stavudine, AZT: Zidovudine, NVP: Nevirapine, EFV: Efavirenz
Percentages do not add up to 100 %, because some subjects had multiple switches.